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Over the past three decades, ovarian cancer re-
mains a major problem of women’s health in the
world, including Indonesia. It is associated with
high morbidity and mortality that is caused by can-
cer. In the world, the incidence of ovarian cancer
in 2008 was 9.4%.1,2 The incidence rate ranks 7th
among cancers in women after breast cancer, col-
orectal, cervical, lung, stomach, and corpus uteri.
Incidence rate of ovarian cancer ranks 3rd among
gynecologic cancers after breast and cervical can-
cer. In some countries, reported that the incidence
of ovarian cancer varied. In 2008, the number of
ovarian cancer cases in the United States is 21,650
cases2 and in the UK is 6,500 cases.3 While in
Europe varies between 12 per 100,000 women in
Southern Europe and 19 per 100,000 women in
Northern Europe in 2008.4
In Asia, the incidence of ovarian cancer is gene-
rally lower than the population in Europe and
Abstract
Objective: To determine the expression of Bcl-2 and caspase-3 and
their relationship with ovarian cancer.
Method: This study was a cross-sectional study. Speciment was tis-
sue sample from ovarian cancer patients collected from parafin-
block to determine the Bcl-2 and caspase-3 expression and demo-
graphic data obtained secondary from patients medical records. Ex-
pression of Bcl-2 and caspase-3 was examined by immunohisto-
chemistry under light microscope with 400x light power field. The
result was recorded as negative when the protein was expressed in
10% or less of cells and as a positive when the protein was ex-
pressed in more than 10% of cells.
Result: A total of 45 samples was included as research subjects. 31
of 45 subjects showed the expression of Bcl-2 positive (68.9%),
while the positive expression of caspase-3 was presented in 20 sub-
jects (44.4%). There was a relationship between the expression of
Bcl-2 with the expression of caspase-3 in ovarian cancer patients
(p=0.002; Lambda=0.4). There was also a negative relationship,
where the subjects with positive expression of Bcl-2 showed nega-
tive expression of caspase-3. In contrast, subjects with negative ex-
pression of Bcl-2 showed positive expression of caspase-3.
Conclusion: There was a significance relationship between the ex-
pression of Bcl-2 with the expression of caspase-3 in ovarian cancer
patients.
[Indones J Obstet Gynecol 2014; 2-1: 33-39]
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Abstrak
Tujuan: Untuk mengetahui ekspresi Bcl-2 dan caspase-3 serta hubun-
gan di antara keduanya pada kanker ovarium.
Metode: Rancangan penelitian adalah potong lintang. Preparat dari
parafin blok pasien-pasien kanker ovarium diperiksa untuk mengeta-
hui ekspresi Bcl-2 dan caspase-3 serta data-data demografi diperoleh
dari catatan medik pasien. Ekspresi Bcl-2 dan caspase-3 diperiksa se-
cara imunohistokimia dengan mikroskop cahaya pada pembesaran
400x. Ekspresi negatif bila jumlah sel yang tercatat sebanyak 10%
atau kurang. Ekspresi positif bila jumlah sel yang tercatat lebih dari
10%.
Hasil: Sebanyak 45 subjek diikutsertakan dalam penelitian. Tiga pu-
luh satu dari 45 subjek memperlihatkan ekspresi Bcl-2 positif (68,9%)
dan 20 subjek memperlihatkan ekspresi caspase-3 positif (44,4%).
Terdapat hubungan antara ekspresi Bcl-2 dengan ekspresi caspase-3
pada kanker ovarium (p=0,002; Lambda=0,4). Juga terdapat hubung-
an negatif, di mana subjek dengan ekspresi Bcl-2 positif memperlihat-
kan ekspresi caspase-3 negatif, sebaliknya subjek dengan ekspresi Bcl-
2 negatif memperlihatkan ekspresi caspase-3 positif.
Kesimpulan: Terdapat hubungan yang bermakna antara ekspresi
Bcl-2 dengan ekspresi caspase-3 pada kanker ovarium.
[Maj Obstet Ginekol Indones 2014; 2-1: 33-39]
Kata kunci: ekspresi Bcl-2, ekspresi caspase-3, kanker ovarium
Correspondence: I Nyoman Gede Budiana. Department of Obstetrics and Gynecology, Sanglah General Hospital/Faculty of Medicine
University of Udayana, Denpasar. Telephone: (0361) 223868, Email: b_d_na@yahoo.com
Vol 2, No 1
January 2014 Expression of Bcl-2 and Caspase-3  33
North America. In Japan, the incidence of ovarian
cancer is increased since 1970, but still lower than
western countries.5 Ushijima (2009) reported the
incidence of ovarian cancer in Japan increased after
the age of 60 and became 10 per 100,000 women.6
In Indonesia, the incidence rate of ovarian cancer
is uncertain. According to the report of Cancer Re-
gister Board Indonesian Ministry of Health that is
obtained from 13 Central Pathology Laboratory in
Indonesia showed that the proportion of ovarian
cancer is 4.9%.7 Reports from some teaching hos-
pital in Indonesia showed that the proportion of
ovarian cancer ranged from 32.5%8 to 35%9.
In addition to the high incidence rate, mortality
rate of ovarian cancer is also high among gyne-
cologic cancers. In the world, the rate of mortality
of ovarian cancer in 2008 is 5.1%.2 The most im-
portant factor that influence the high mortality rate
of ovarian cancer is 70-75% of cases diagnosed at
an advanced stage even terminal where 5-year sur-
vival rate is 20 - of 30%. However, when found in
stage I, the 5-year survival rate reach 90-95%.10
Thus, although the incidence of ovarian cancer was
on the 3rd place, but the cancer is the number one
cause of death among gynecological cancers.
The difficulty of finding ovarian cancer at an
early stage related to the difficulty of finding the
accurate screening and early detection methods.
There are many effort in early diagnosis of ovarian
cancer, but until now there have not been found a
satisfactory method. Screening modality such as ul-
trasound, tumor markers CA-125, α-fetoprotein,
and other efforts have not been able to reduce the
incidence and mortality rate of ovarian cancer.
Similarly, several attempts therapy such as surgery,
chemotherapy, and radiation, as monotherapy or
combination has not been given satisfactory re-
sults. On the other hand, knowledge and research
in the field of molecular biology is become more
advanced. Treatment of ovarian cancer through the
understanding of the carcinogenic mechanisms be-
come more promising in the future.
One mechanism to control cell growth is a pro-
cess of programmed cell death or apoptosis. This
mechanism is a complex process and involves a va-
riety of proteins, one of them is the protein Bcl-2
and caspase-3. Bcl-2 proteins work against the p53
tumor suppressor protein that disrupt cell cycle
regulation. The cells will undergo proliferation and
resistance to stimulation that would normally lead
to cells death.11 Several studies have reported that
expression of Bcl-2 in ovarian cancer was signifi-
cantly higher than in benign tumor.12 Meanwhile,
caspase-3 protein is one of the 14 caspase that is
known by human.13 Caspase-3 acts as an apoptosis
executor and cell death due to specific stimuli. In
addition, caspase-3 plays an important role in the
changes in cell morphology and biochemical events
associated with the implementation and complete
the process of apoptosis.14 There is a significant
difference in the expression of caspase-3 in epi-
thelial ovarian cancer, borderline ovarian tumors,
benign ovarian tumors, and normal ovarian tissue.
Caspase-3 is also a factor of poor prognosis in epi-
thelial ovarian cancer.15
Studies of oncogenes, tumor suppressor genes
and proteins involved in the process of apoptosis
in ovarian cancer have been carried out. However,
most research only focused on a single gene, and
in high-risk families so that the results are less re-
presentative in extrapolation. Protein expression of
Bcl-2 and caspase-3 are known to differ in malig-
nant ovarian tumors, boderline, benign, and nor-
mal ovarian cells. However, no one has studied the
relationship between the expression of these pro-
teins in ovarian cancer. The relationship between
protein Bcl-2 and caspase-3 is involved in apop-
tosis process will contribute to the role of both pro-
teins in ovarian cancer carcinogenesis. In the fu-
ture, a growing number of proteins are known to
play a role in the carcinogenesis of ovarian cancer,
there are more effort in screening method, early
diagnosis, and genetic therapies that can be applied
to reduce the incidence and mortality rate of ova-
rian cancer.
METHODS
This study is an observational study with cross-
sectional design. Subjects were patients with ova-
rian cancer tissues obtained from laparotomy sur-
gery in Sanglah Hospital in Denpasar, which is
based on histopathologic examination that is
known as malignant ovarian tumors (ovarian can-
cer). Ovarian cancer classification refers to the clas-
sification of WHO in 2003.16 Ovarian tumors tissue
that have parrafined and stored in Laboratory of
Pathology Anatomi, Faculty of Medicine, Udayana
University/Sanglah Hospital in Denpasar, which
was diagnosed with ovarian cancer based on his-
topathological examination, was selected as re-
search subjects. Inclusion criteria were: a block of
paraffin was examined histopathologically, so it
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was definitely diagnosed as ovarian cancer, the pa-
tient’s medical records can be found, and the nec-
essary data is complete. While the exclusion crite-
ria were: patients who had been given chemo/ra-
diotherapy preoperatively, the tissue was damaged
due to various technical reasons, the patient’s
medical records could not be found or the neces-
sary data was not complete.
Ovarian cancer tissue that has been prepared
into paraffin block then processed for immunohis-
tochemical examination of Bcl-2 and caspase-3
protein. Epidemiological data of patient is obtained
secondary from patients medical records that is re-
corded on the data collection sheet. Examination of
protein expression of Bcl-2 and caspase-3 was per-
formed by immunohistochemistry. Bcl-2 protein
expression examined using monoclonal antibody
staining methode specific primary monoclonal
mouse anti-human Bcl-2 protein clone 124, while
caspase-3 protein expression examined using bio-
tin-avidin indirect staining of primary mouse mo-
noclonal antibody (Triton, Alameda, CA). Protein
expression of Bcl-2 and caspase-3 was assessed
semiquantitatively under light microscope with
400x light power light. Expression positive if pro-
tein was expressed in more than 10% of cells,
whereas expression negative if protein was ex-
pressed in 10% or less of cells.
RESULTS
We examined the expression of Bcl-2 and caspase-
3 and the complete of patient’s medical record in
45 subjects. Of the 45 subjects, the youngest age
was 19 years old, the oldest was 70 years old, the
median age was 43 years old with mean age of sub-
jects was 41.3 ± 13.7 years. The most common age
group patients with ovarian cancer is over 50 years
old (24.4%).
Table 1. Characteristics of Subjects.
Characteristics Total (%)
Age group (years)
• ≤ 20 1 (2.2)
• 21 - 25 7 (15.6)
• 26 - 30 4 (8.8)
• 31 - 35 7 (15.6)
• 36 - 40 1 (2.2)
• 41 - 45 7 (15.6)
• 46 - 50 7 (15.6)
• > 50 11 (24.4)
Parity
• 0 22 (48.9)
• 1 5 (11.1)
• 2 8 (17.8)
• 3 4 (8.9)
• 4 2 (4.4)
• ≥ 4 4 (8.9)
Histopathological type
• Musinus 3 (6.7)
• Endometrioid 3 (6.7)
• Serus 26 (57.8)
• Seromukus 1 (2.2)
• Clear-cell 1 (2.2)
• Germ-cell 6 (13.3)
• Teratomaimmature 2 (4.4)
• Granulosa cell tumor 3 (6.7)
Stage of disease
• IA 4 (8.9)
• IB 1 (2.2)
• IC 14 (31.2)
• IIC 1 (2.2)
• IIIB 9 (20.0)
• IIIC 10 (22.2)
• IV 6 (13.3)
Bcl-2 expression
• Positive 31 (68.9)
• Negative 14 (31.1)
Caspase-3 expression
• Positive 20 (44.4)
• Negative 25 (55.6)
Total 45 (100)
Relationship between Expression of Bcl-2
with Expression of Caspase-3
Table 2 shows the relationship between the ex-
pression of Bcl-2 with the expression of caspase-3
(p=0.002; Lambda=0.4). There are negative rela-
tionship also, where the subjects with positive ex-
pression of Bcl-2 showed negative expression of
caspase-3. In contrast, subjects with negative ex-
pression of Bcl-2 showed positive expression of
caspase-3. Based on stage of disease, the expres-
sion of Bcl-2 positive is increasing along with the
stage of disease (p=0.002; Lambda=0.1). Mean-
while, subject with positive expression of caspase-3
is getting higher on early-stage disease, in contrast
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to subject with advanced stage of disease showing
negative expression of caspase-3 (p=0.000; Lamb-
da=0.3).
Table 2. Relationship between Expression of Bcl-2 with





Expression Positive 22 9 31 p=0.002
of Bcl-2 Negative 3 11 14 Lambda=0.4
Total 25 20 45
DISCUSSION
In this study we found the proportion of ovarian
cancer on patients aged 20 years old was 2.2%,
with the largest proportion were in the age group
over 50 years old. These results are similar with
the data from SEER cancer statistic review report-
ing that the proportion of ovarian cancer at the age
under 20 years old was 1.3%. While the largest
proportion occurred in the age group of 55-64
years old were as many as 23.4%.17
These results are consistent with the reports in
the published literature that stated the incidence
of ovarian cancer is increased along with the age.
Ovarian cancer is very rarely occurred under 40
years old.18 Peak incidence of ovarian cancer oc-
curs at age 50 years old, and increasing gradually
until 70 years old, then decline after 80 years old.19
Parity in this study ranged from 0-9. The largest
proportion of patients with parity 0 is 48.9%.
There is a trend of the larger parity proportion, the
lower incidence of ovarian cancer, where parity
that is more that 4 is as many as 8.9%.
Research by Rivas-Corchado LM et al found that
from 40 ovarian cancer patients, 25% occurred in
patients with parity 0.20 Several studies have found
the risk of epithelial ovarian cancer is higher in
women with higher social economy status. This is
related with only a few of those women have chil-
drends.21 Parity is a factor that increases the risk
of ovarian cancer. The risk of ovarian cancer is de-
creased along with the increasing number of preg-
nancy.18 Multiparity is associated with a reduced
risk of ovarian cancer.22
Protective effect against the development of ova-
rian cancer such as multiparity, supports the con-
cept of incessant ovulation which is a contributing
factor in the development of ovarian cancer. This
concept was first proposed by Fathalla.23 The risk
of ovarian cancer is associated with the number of
ovulatory cycles. When ovulation occurs, the epi-
thelium surface was damaged. The epithelial dam-
age stimulates epithelial cells to undergo prolifera-
tion as an attempt to repair. At the time of ovula-
tion, invagination of epithelial surface into the
stroma and form inclusion cyst also occured.18 Sub-
sequent researchers found that the process that in-
volved in the repairment of damaged ovarian epi-
thelial surface that caused by traumatic ovulation
particularly epithelial that cover inclusion cyst un-
der the influence of oncogenic factors somehow
will turn to malignancy. The larger number of life-
time ovulatory cycles in women, the higher her risk
of developing epithelial ovarian cancer.24,25
From 45 subjects, the commonest histopatho-
logic type was serous (57.8%). While the rare of
histopathologic type is clear-cell type and seromu-
cous 2.2%, respectively.
Research by Rivas-Corchado LM, et al suggested
that the commonest histopathological type of ovar-
ian cancer is serous, accounted for 25%, followed
by endometrioid and mucinous types (20% for
each type) and granulosa cell types (7%).20 In
other literature ovarian cancer serous type re-
mains the commonest, accounted for 75%, fol-
lowed by mucinous (20%) and endometrioid (2%).
While the clear-cell, Brenner, and undifferentiated
carcinoma are found to be less than 1%, respec-
tively.16
Stage of Disease
Based on the stage of disease, from 45 subjects,
there are no subjects with stage IIA, IIB, and IIIA.
Stage IC has the largest proportion (31.2%). In con-
trast with the results of study by Rivas-Corchado
LM, et al that found most cases in stage IA (32%).
But cumulatively, the number of cases with ad-
vanced stage (stage III and IV) remains higher
(55.5%) compared with early stage (stage I and II),
which is only 44.5%.20
Report from ACOG Committee Opinion in 2002
found that as many as 70-75% of ovarian cancer
cases are diagnosed at advanced stage.10 This is an
important factor that affect the high mortality rate
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of ovarian cancer, where the 5-year survival rate
at advanced stage is 20 - of 30%. However, when
found in stage I, the 5-year survival rate reach 90-
95%.10
Relationship between Bcl-2 and Caspase-3
Expression
In this research, the rate of positive expression of
Bcl-2 in ovarian cancer was 68.9%, while the rate
of negative expression of Bcl-2 was 31.1%. The
similar results also obtained in a cohort study with
95 advanced ovarian cancer patients (stage IIIC-IV)
that found the results of immunohistochemical ex-
amination toward positive protein Bcl-2 rate of
69.5%.26 While other studies that involving 71
ovarian tumors serous, including 29 benign ovar-
ian tumors, 14 borderline ovarian tumors, and 28
malignant ovarian tumors found the positive ex-
pression of Bcl-2 17.2%, 35.7%, and 25%, respec-
tively.27
Meanwhile, the positive expression of caspase-3
in this study is 44.4%, with the negative expression
of caspase-3 is 55.6%. These results are similar
with results of other studies, which examine the
expression of caspase-3 by immunohistochemistry
in 16 cases of benign ovarian tumors and 84 cases
of ovarian cancer. Postive expression of caspase-3
is 93.4% in benign ovarian tumors and 48.8% in
cancer ovarium.28 Likewise, research on 112 cases
of primary ovarian tumor, found positive caspase-3
expression in malignant ovarian tumors for 44, 4%
which is significantly lower than the expression of
caspase-3 in benign ovarian tumors that is 81.8%
(p=0.01).29 The expression of caspase-3 in ovarian
cancer are consistently lower than the expression
of caspase-3 in benign ovarian tumor and normal
ovarian tissue.30,31
In this study we also found a significant corre-
lation between the expression of Bcl-2 with the ex-
pression of caspase-3 in ovarian cancer (p=0.002).
Table 2 showed that in the group with positive ex-
pression of Bcl-2, we also found cases with nega-
tive expression of caspase-3. And vice versa, when
there are group of negative expression of the Bcl-2,
there are also cases with positive expression of
caspase-3. This suggests a negative relationship,
cases with positive expression of Bcl-2 have nega-
tive expression of caspase-3, while the opposite
cases with negative expression of Bcl-2 have a posi-
tive expression of caspase-3 (p=0.002; Lambda=0,
4).
On the mechanism of apoptosis, either through
the extrinsic and intrinsic pathways, it is known
that Bcl-2 acts as an anti apoptosis either through
inhibit the release of cytochrome-c from mitochon-
dria or by inhibiting the activity of caspase includ-
ing caspase-3.32 Caspase-3 is the most important
executioner caspase among another executioner
such as caspase-6 and caspase-7. Caspase-3 activity
involved many substrates such as cytokeratin,
PARP, fodrin cytoskeleton protein alpha plasma
membrane, the protein core, and activate CAD en-
donuclease.33 Activity of these proteins causes
changes in morphology and biochemistry as seen
in apoptotic cells include shrunken cells, protein
condensation, chromosomal DNA fragmentation,
degradation of the core including cytoskeleton pro-
teins, and cells disintegration becoming apoptotic
bodies.14,34 In the mechanism of apoptosis, Bcl-2
activity is inversely proportional to caspase-3,
where Bcl- 2 acts as an anti-apoptosis, while cas-
pase-3 acts as executioner apoptosis.
Relationship of Bcl-2 and Caspase-3 Ex-
pression with Stage of Disease
When associated with stage of disease, there is a
significant correlation between the expression of
Bcl-2 with stage of disease (p=0.002). This study
showed the positive expression of Bcl-2 is increas-
ing along with the higher stage of disease (p=0.002;
Lambda = 0.3). Another studies found that the ex-
pression of Bcl-2 positively related to unfavorable
factors such as the degree of differentiation of the
cells, advanced stage disease, and residual tumor.35
Meanwhile, Lukyanova NY, et al found that the ex-
pression of Bcl-2 is decreased in patients with ova-
rian cancer with a good degree of cell differentia-
tion and in patients with early stage ovarian can-
cer.36 In contrast, the expression of Bcl-2 is
increased along with the increasing degree of cell
differentiation and stage of disease.27 This finding
is consistent with the role of Bcl-2 in apoptosis me-
chanism as an anti-apoptotic as described above.
Besides the relationship between the expression
of Bcl-2 with stage of disease, the present study
also found a significant correlation between the ex-
pression of caspase-3 with stage of disease
(p=0.000). Subjects with positive expression of cas-
pase-3 is higher on the early-stage disease, in con-
trast to the advanced stage that showed negative ex-
pression of caspase-3 (p=0.000; Lambda=0.3). An-
other studies have also found similar results, in
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which the expression of caspase-3 in malignant
ovarian tumors is significantly associated with the
degree of cell differentiation and stage of dis-
ease.29-31 In accordance with the role of caspase-3
in apoptosis mechanisms as an executioner cas-
pase, then higher expression of caspase-3 means
that the apoptotic mechanism went well. Con-
versely, if the expression of caspase-3 is low, apop-
tosis process will become impaired that will cause
the stage of disease will be more advanced.
CONCLUSIONS
In this research, positive expression of Bcl-2 in
ovarian cancer is 68.9%, while the expression of
caspase-3 in ovarian cancer is 44.4%. Statistically,
there is a significant association between the ex-
pression of Bcl-2 and the expression of caspase-3
in ovarian cancer. There was also a significant as-
sociation between the expression of Bcl-2 and
caspase-3 expression with stage ovarian cancer
stage. The results of this study indicate a role of
Bcl-2 and caspase-3 in ovarian cancer that can be
used to develop strategies for diagnosis, treatment,
and prognosis based on molecular mechanism.
Further research is needed with better research
methods such as case-control or cohort study.
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